Elite Pharmaceuticals (OTCMKTS:ELTP – Get Free Report) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Elite Pharmaceuticals had a net margin of 30.14% and a return on equity of 37.06%.
Elite Pharmaceuticals Stock Down 0.4%
OTCMKTS ELTP traded down $0.00 during trading on Thursday, hitting $0.36. The company’s stock had a trading volume of 913,100 shares, compared to its average volume of 617,123. Elite Pharmaceuticals has a fifty-two week low of $0.33 and a fifty-two week high of $0.74. The company has a market cap of $386.15 million, a PE ratio of 17.93 and a beta of 0.40. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.45 and a quick ratio of 5.22. The business’s 50 day simple moving average is $0.37 and its 200-day simple moving average is $0.38.
Elite Pharmaceuticals Company Profile
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.
Featured Stories
- Five stocks we like better than Elite Pharmaceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
